

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 June 2022 (09.06.2022)



(10) International Publication Number
WO 2022/120292 A1

(51) International Patent Classification:

A61P 7/04 (2006.01) C12N 15/113 (2010.01)
A61P 43/00 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/062078

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

06 December 2021 (06.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/121,973 06 December 2020 (06.12.2020) US
63/272,629 27 October 2021 (27.10.2021) US
63/275,344 03 November 2021 (03.11.2021) US

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: GENZYME CORPORATION [US/US]; 50
Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: POLOSKEY, Stacey; c/o Sanofi, 55 Corporate Drive - Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). ANDERSSON, Shauna; c/o Sanofi, 55 Corporate Drive - Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). BHAGUNDE, Pratik R.; c/o Sanofi, 55 Corporate Drive - Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). CUI, Yue; c/o Sanofi, 55 Corporate Drive - Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). IQBAL, Sajida; c/o Sanofi, 55 Corporate Drive - Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). MEI, Baisong; Sanofi, 55 Corporate Drive - Mail Code 55A-525, Bridgewater, New Jersey 08807 (US).

(74) Agent: LI, Z. Ying et al.; Steptoe & Johnson LLP, 1330 Connecticut Avenue, N.W., Washington, District of Columbia 20036 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: TREATMENT OF HEMOPHILIA WITH FITUSIRAN

(57) Abstract: The present disclosure provides a method that aims to maintain a favorable benefit-risk balance for patients with hemophilia A or B with or without inhibitors treated with fitusiran.

WO 2022/120292 A1